Compare GFF & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GFF | AMLX |
|---|---|---|
| Founded | 1959 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.8B |
| IPO Year | 1994 | 2021 |
| Metric | GFF | AMLX |
|---|---|---|
| Price | $97.59 | $33.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $105.00 | $21.56 |
| AVG Volume (30 Days) | 265.5K | ★ 3.2M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.99% | N/A |
| EPS Growth | N/A | ★ 65.46 |
| EPS | ★ 2.97 | N/A |
| Revenue | ★ $2,519,926,000.00 | $380,786,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $33.56 | ★ N/A |
| Revenue Growth | N/A | ★ 1612.94 |
| 52 Week Low | $65.01 | $10.83 |
| 52 Week High | $108.57 | $41.14 |
| Indicator | GFF | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 48.19 | 61.73 |
| Support Level | $88.43 | $32.98 |
| Resistance Level | $108.57 | $41.14 |
| Average True Range (ATR) | 2.42 | 2.06 |
| MACD | -0.72 | -0.66 |
| Stochastic Oscillator | 32.82 | 10.42 |
Griffon Corp manufactures and markets residential, commercial and industrial garage doors to professional installing dealers and home center retail chains. It also provides non-powered landscaping products for homeowners and professionals. Its operating segments include Consumer and Professional Products: is a provider of branded consumer and professional tools; residential, industrial and commercial fans; home storage and organization products; and Home and Building Products conducts its operations through Clopay Corporation (Clopay). Clopay is the manufacturer and marketer of garage doors and rolling steel doors in North America. The company generates a majority of its revenue from the Home and Building Products segment. Operates in USA, Europe, Canada, Australia, and Others.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.